Company intelligence / Profile preview
Hong Kong WD Pharmaceutical Co., Limited
Hong Kong, Hong Kong SAR, Chinaen.wdpharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has completed a Phase 2 clinical trial for WD-1603 (carbidopa/levodopa controlled-release tablets) in Parkinson's disease patients. Another Phase 2 trial (CTRI/2023/12/060430) for WD-1905 tablets compared with SINEMET® in Parkinson's Disease subjects with Morning Akinesia was initiated in December 2023 but is not yet recruiting[1][3].
- Therapeutic areas
- Neurology
- Modalities
- Small moleculescontrolled-release formulations
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Hong Kong WD Pharmaceutical Co., Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hong Kong WD Pharmaceutical Co., Limited.